AVEO AVEO Pharmaceuticals Inc.

0.72
+0.11  (+17%)
Previous Close 0.62
Open 0.64
Price To Book -1.51
Market Cap 90776006
Shares 125,346,598
Volume 13,627,302
Short Ratio
Av. Daily Volume 2,984,140

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation announced December 7, 2017.
Ficlatuzumab and cetuximab
Head and neck squamous cell carcinoma (HNSCC)
Phase 2 data at ESMO 2018 noted 56% ORR.
Tivozanib + Opdivo
Renal cell cancer (RCC)
Announced September 12, 2016 that its Phase 2 trial has been discontinued
Ficlatuzumab
EGFR-mutated Non-small cell lung cancer (NSCLC)
Interim OS outcome due 4Q 2019,
TIVO-3 - tivozanib
Third line treatment of patients with renal cell cancer

Latest News

  1. AVEO Oncology Announces Oral Presentation of TIVO-3 Trial Topline Results at the 2019 ASCO Genitourinary Cancers Symposium
  2. The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO
  3. Biotech Stock Roundup: Celgene Tops in Q4, Gilead Disappoints, ALKS & AVEO Sink
  4. Bragar Eagel & Squire, P.C. is Investigating AVEO Pharmaceuticals, Inc. (AVEO) on Behalf of Stockholders and Encourages AVEO Investors to Contact the Firm
  5. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of AVEO Pharmaceuticals, Inc.
  6. AVEO Oncology Plunges on Delay in Filing Fotivda NDA With FDA
  7. Aveo Pharmaceuticals Stock Fell More than 60% on January 31
  8. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AVEO Pharmaceuticals, Inc. (AVEO)
  9. Why AVEO Oncology Stock Is Crashing Today
  10. Aveo stock plunges after delay in FDA approval submission for cancer drug
  11. AVEO Oncology Announces NDA Timing Update
  12. Report: Exploring Fundamental Drivers Behind Realty Income, United Therapeutics, NxStage Medical, PTC Therapeutics, AVEO Pharmaceuticals, and Owens & Minor — New Horizons, Emerging Trends, and Upcoming Developments
  13. Options Traders Expect Huge Moves in AVEO Pharmaceuticals (AVEO) Stock
  14. How to spot risky biotech companies and six to avoid now
  15. Here's Why These Small-Cap Pharma Stocks Lost as Much as 45% in December
  16. AVEO Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference
  17. AVEO Oncology to Present TIVO-3 Data at the 2019 ASCO Genitourinary Cancers Symposium
  18. 4 Pharma Stocks Heating Up On Wednesday (12/26/18)
  19. Is AVEO Pharmaceuticals, Inc. (AVEO) A Good Stock To Buy?
  20. Do Options Traders Know Something About AVEO Pharmaceuticals (AVEO) Stock We Don't?

SEC Filings

  1. 8-K - Current report 19611999
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19602051
  3. SC 13G - Statement of acquisition of beneficial ownership by individuals 19576474
  4. 8-K - Current report 19572435
  5. 8-K - Current report 181242148
  6. CT ORDER - Confidential treatment order 181215504
  7. CT ORDER - Confidential treatment order 181215501
  8. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 181205744
  9. 8-K - Current report 181171342
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 181171273